Clinical effect of Trimetazidine in the treatment of hypertensive heart disease
YANG Hui ZHONG Jianghua SU Yujiang MA Tianyi
Department of Cardiovascular Medicine, Haikou People′s Hospital (Haikou Hospital Affiliated to Xiangya Hospital, Central South University), Hainan Province, Haikou 570208, China
Abstract：Objective To study the clinical effect of Trimetazidine in the treatment of hypertensive heart disease. Methods A total of 80 patients with hypertensive heart disease admitted to Haikou Hospital Affiliated to Xiangya Hospital Central South University were selected as the research object. According to the random number table method, they were divided into experimental group and routine group, with 40 cases in each group. The conventional group was treated with conventional therapy, and the experimental group was treated with Trimetazidine Tablets on the basis of the conventional group. The dosage of Trimetazidine Tablets was 20 mg/time, 3 times/day, and the patients in both groups were treated for 3 months. Clinical treatment effect, clinical symptoms, cardiac function changes and adverse symptoms were compared between the two groups. Results After treatment, the overall productivity of the experimental group was higher than that of the conventional group, and the difference was statistically significant (P ＜ 0.05). After treatment, the frequency of angina pectoris, the duration of angina pectoris and the amount of nitroglycerin used in the experimental group were all lower than those in the conventional group, and the amount of exercise for 7 min was higher than that in the conventional group, with statistically significant differences (all P ＜ 0.05). Before treatment, there was no statistically significant difference in left ventricular ejection fraction (LVEF), left ventricular end-systolic volume index (LVESVI) and left ventricular end-diastolic volume index (LVEDVI) between the two groups (P ＞ 0.05). After treatment, LVEF in the two groups was higher than that before treatment, LVESVI and LVEDVI were lower than those before treatment, and LVEF in the experimental group was higher than that in the conventional group, and LVESVI and LVEDVI were lower than those in the conventional group, with statistically significant differences (all P ＜ 0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse symptoms between the two groups (P ＞ 0.05). Conclusion The use of Trimetazidine on the basis of conventional drug treatment can significantly increase the curative effect of patients with hypertensive heart disease, can significantly reduce the frequency of angina pectoris and the amount of nitroglycerin, can under the premise of the control of blood pressure, make the patient′s heart function and exercise were promoted, so as to improve the prognosis of patients.
阳慧 钟江华 苏雨江 马添翼. 曲美他嗪治疗高血压性心脏病的临床效果[J]. 中国医药导报, 2020, 17(10): 149-152.
YANG Hui ZHONG Jianghua SU Yujiang MA Tianyi. Clinical effect of Trimetazidine in the treatment of hypertensive heart disease. 中国医药导报, 2020, 17(10): 149-152.
2020, Vol. 17 
京公网安备 11010502046598号